Safety and efficacy of an all-oral interferon-free regimen of seraprevir, an NS3/4A protease inhibitor and sofosbuvir in patients with chronic hepatitis C virus (HCV) genotype 1: an open-label, multicentre, phase 3 trial

被引：0

作者：

Wen, Xiaoyu ^{[1
]}

Kong, Fei ^{[1
]}

Wen, Xiaofeng ^{[2
]}

Wang, Xiaozhong ^{[3
]}

Lin, Shide ^{[4
]}

Wu, Guicheng ^{[5
]}

Wang, Li ^{[6
]}

Xing, Huichun ^{[7
]}

Yan, Xuebing ^{[8
]}

Zheng, Sujun ^{[9
]}

Ning, Qin ^{[10
]}

Wang, Zheng ^{[11
]}

Zhang, Liaoyun ^{[12
]}

Li, Jianmei ^{[13
]}

Tong, Zhaowei ^{[14
]}

Su, Minghua ^{[15
]}

Tong, Lixin ^{[16
]}

Huang, Chengyu ^{[17
]}

Jia, Ji-Dong ^{[18
]}

Xin, Yongning ^{[19
]}

Zhu, Qingjing ^{[20
]}

Wang, Jing ^{[21
]}

Zhang, Yuexin ^{[22
]}

Li, Guangming ^{[23
]}

Niu, Junqi ^{[1
]}

机构：

[1] First Hosp Jilin Univ, Hepatol, Changchun, Peoples R China

[2] Liuzhou Peoples Hosp, Liuzhou, Peoples R China

[3] Xinjiang Uygur Autonomous Reg Tradit Chinese Med, Tibetan, Peoples R China

[4] Zunyi Med Coll, Affiliated Hosp, Zunyi, Guizhou, Peoples R China

[5] Chongqing Three Gorges Cent Hosp, Chongqing, Peoples R China

[6] Chengdu Publ Clin Hlth & Med Ctr, Chengdu, Peoples R China

[7] Capital Med Univ, Beijing Ditan Hosp, Beijing, Peoples R China

[8] Xuzhou Med Univ, Affiliated Hosp, Xuzhou, Jiangsu, Peoples R China

[9] Capital Med Univ, Beijing Youan Hosp, Beijing, Peoples R China

[10] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China

[11] Fifth Hosp Wuxi, Wuxi, Jiangsu, Peoples R China

[12] Shanxi Med Univ, Hosp 1, Jinzhong, Peoples R China

[13] Sichuan Prov Peoples Hosp, Chengdu, Peoples R China

[14] Huzhou City Cent Hosp, Huzhou, Peoples R China

[15] Guangxi Med Univ, Hosp 1, Nanning, Peoples R China

[16] Hebei Med Univ, Hosp 1, Shijiazhuang, Hebei, Peoples R China

[17] Chongqing Publ Clin Hlth & Med Ctr, Chongqing, Peoples R China

[18] Capital Med Univ, Beijing Friendship Hosp, Beijing, Peoples R China

[19] Qingdao City Cent Hosp, Qingdao, Peoples R China

[20] Jinyintan Hosp Wuhan, Wuhan, Peoples R China

[21] Southwest Med Univ, Tradit Chinese Med Hosp, Luzhou, Peoples R China

[22] Xinjiang Med Univ, Hosp 1, Urumqi, Peoples R China

[23] Zhengzhou Sixth Peoples Hosp, Zhengzhou, Peoples R China

来源：

JOURNAL OF HEPATOLOGY | 2020年 / 73卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

THU391

引用

页码：S330 / S330

页数：1

共 50 条

[31] Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial
Andrieux-Meyer, Isabelle
Tan, Soek-Siam
Thanprasertsuk, Sombat
Salvadori, Nicolas
Menetrey, Caroline
Simon, Francois
Cressey, Tim R.
Said, Hajjah Rosaida Hj Mohd
Abu Hassan, Muhammad Radzi
Omar, Haniza
Tee, Hoi-Poh
Chan, Wah Kheong
Kumar, Suresh
Thongsawat, Satawat
Thetket, Kanawee
Avihingsanon, Anchalee
Khemnark, Suparat
Yerly, Sabine
Ngo-Giang-Huong, Nicole
Siva, Sasikala
Swanson, Alistair
Goyal, Vishal
Bompart, Francois
Pecoul, Bernard
Murad, Shahnaz
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (06): : 448 - 458
[32] Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial
Asselah, Tarik
Hezode, Christophe
Qaqish, Roula B.
ElKhashab, Magdy
Hassanein, Tarek
Papatheodoridis, George
Feld, Jordan J.
Moreno, Christophe
Zeuzem, Stefan
Ferenci, Peter
Yu, Yao
Redman, Rebecca
Pilot-Matias, Tami
Mobashery, Niloufar
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2016, 1 (01): : 25 - 35
[33] Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial
Waked, Imam
Shiha, Gamal
Qaqish, Roula B.
Esmat, Gamal
Yosry, Ayman
Hassany, Mohamed
Soliman, Reham
Mohey, Mohammad A.
Allam, Naglaa
Zayed, Naglaa
Asselah, Tarik
Hall, Coleen
Redman, Rebecca
Mobashery, Niloufar
Doss, Wahid
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2016, 1 (01): : 36 - 44
[34] Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial
Forns, Xavier
Lee, Samuel S.
Valdes, Joaquin
Lens, Sabela
Ghalib, Reem
Aguilar, Humberto
Felizarta, Franco
Hassanein, Tarek
Hinrichsen, Holger
Rincon, Diego
Morillas, Rosa
Zeuzem, Stefan
Horsmans, Yves
Nelson, David R.
Yu, Yao
Krishnan, Preethi
Lin, Chih-Wei
Kort, Jens J.
Mensa, Federico J.
LANCET INFECTIOUS DISEASES, 2017, 17 (10): : 1062 - 1068
[35] ANTIVIRAL EFFICACY OF THE NS3 PROTEASE INHIBITOR, GS-9451, NON-NUCLEOSIDE NS5b INHIBITOR, TEGOBUVIR, AND PEGYLATED INTERFERON PLUS RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 1 HEPATITIS C INFECTED PATIENTS
Pol, S.
Jablkowski, M.
Trenkle, J. D.
Kanwar, B.
Bekele, B. N.
Subramanian, M.
McHutchison, J. G.
Flamm, S. L.
Muir, A. J.
JOURNAL OF HEPATOLOGY, 2013, 58 : S31 - S31
[36] Efficacy and safety of alfosbuvir plus daclatasvir in Chinese patients with hepatitis C virus genotypes 1, 2, 3, and 6 infection: An open-label, phase 2 study
Hua, Rui
Kong, Fei
Wen, Xiaofeng
Xiong, Qingfang
Chen, Jiayu
Meng, Chenxin
Ma, Hong
Tan, Youwen
Huang, Yan
Jiang, Yongfang
Guan, Yujuan
Mao, Xiaorong
Wang, Jiefei
Xin, Yongning
Gao, Hainv
Xu, Bin
Li, Cheng
Wu, Qiong
Zhang, Xian
Wang, Zhiqiang
Zhao, Liwen
Zhang, Yuexin
Li, Guangming
Niu, Junqi
JOURNAL OF VIRAL HEPATITIS, 2022, 29 (06) : 455 - 464
[37] Viral Resistance in Hepatitis C Virus Genotype 1-Infected Patients Receiving the NS3 Protease Inhibitor Faldaprevir (BI 201335) in a Phase 1b Multiple-Rising-Dose Study
Berger, Kristi L.
Lagace, Lisette
Triki, Ibtissem
Cartier, Mireille
Marquis, Martin
Lawetz, Carol
Bethell, Richard
Scherer, Joseph
Kukolj, George
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (10) : 4928 - 4936
[38] Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial (vol 6, pg 448, 2021)
Andrieux-Meyer, I
Tan, S-S
Thanprasertsuk, S.
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (08): : 704 - 704
[39] Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial (vol 1, pg 36, 2016)
Waked, I
Shiha, G.
Qaqish, R. B.
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2016, 1 (01): : E1 - E1
[40] A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin
Wei, Lai
Zhang, Mingxiang
Xu, Min
Chuang, Wan-Long
Lu, Wei
Xie, Wen
Jia, Zhansheng
Gong, Guozhong
Li, Yueqi
Bae, Si Hyun
Yang, Yong-Feng
Xie, Qing
Lin, Shumei
Chen, Xinyue
Niu, Junqi
Jia, Jidong
Garimella, Tushar
Torbeyns, Anne
McPhee, Fiona
Treitel, Michelle
Yin, Philip D.
Mo, Ling
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 (11) : 1860 - 1867

← 1 2 3 4 5 →